Nivolumab and axitnib for metastatic melanoma – pro
Although Inlyta is FDA-approved for use with pembrolizumab, nivolumab and axitinib is nto a well-studies regimen.
INLYTA, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA, in combination with pembrolizumab, is indicated for the first-line treatment of patients with advanced RCC. There is an open trial for it in mucosal melanoma, which is a somewhat different disease.
For cutaneous melanoma, there is phase II trial ( NCT04493203) evidence. published as an abstract, 31 of planned 31 pts have been enrolled in January 2024, with no data analysis yet available. .Another trial showed that this combination is tolerable, but again, no results on efficacy. As such, this is currently an E/I approach.
Urvashi Mitbander Joshi, Saba Shaikh, Yan Zang, Hong Wang, Cindy Sander, Amy Rose, Diwakar Davar, Jason J. Luke, Hassane M. Zarour, John M. Kirkwood, Greg M Delgoffe, and Yana G. Najjar, A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.Meeting Abstract: 2024 ASCO Annual Meeting Journal of Clinical Oncology Volume 42, Number 16_suppl
See abstract at https://jitc.bmj.com/content/8/Suppl_3/A265.1, J Immonology 2020
Zibelman MR, Carducci MA, Ged Y, et al. A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(suppl 6):291. doi:10.1200/JCO.2022.40.6_suppl.291